i ignored my stop loss rule on this one because this stock is a back room "good ole boys" deal going down and shares will be hard to come by when it rolls. of course now i wish i had of sold so i could have tripled my stake in it. i have done in depth dd and the value here is in the relationships of the (even though less than desirable and somewhat tainted) management and the power, influence they yield and also current SS of company. their past post range from white house drug policy deputy director (joseph peters) under clinton and bush for state and local affairs, who was and is a respected media commentator, recognized for his expert insight on law enforcement, counter terrorism issues and technology. then there is edward rollins who advised many fortune 500 companies, heads of state and 4 usa presidents. he also worked in office of intergovernmental affairs and was deputy chief of staff under reagan (not to mention he ran a huge part of Trumps campaign)
plus several others who are well connected to nasa and the drug development and manufacturing process. they ALSO have recruited top talent in nanotech with proven track records of bringing products to market. this is all headed up by steven stienbuhl director of scripps translation science with 25 years of medical expertIse and FDA connections. add all this up and i see shortcut after shortcut and a clear advantage from ANY angle over the competition. ESPECIALLY since Trump was elected. LIKE I SAID...GOOD OLE BOYS CLUB!!! LOAD EM UP WHILE YO CAN!!!!!
